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Inherited factor VII (FVII) deficiency is a rare disorder characterized by a bleeding phenotype varying from mild to
severe. To date, more than 200 mutations have been described along the F7 gene encoding for FVII. The aim of
this study was the identification of genetic defects underlying FVII deficiency in 10 patients belonging to eight
unrelated families of the North provinces from Tunisia. Mutation detection was performed by sequencing the
whole F7 gene coding region, exon-intron boundaries and about 400 bp of the promoter region. We identified 5
mutations in five unrelated families; the novel p.F328Y mutation and the reported mutations: p.R304Q, p.M298I,
IVS1aG> A and p.G-39G. For the remaining 5 patients we didn’t identified any mutations using PCR/Sequencing
protocol. In conclusion, this study represents the first comprehensive molecular series of FVII deficiency affected
patients in Tunisia from the North. We will try in the future to continue the molecular study for Tunisian patients
from Center and South provinces in order to have a complete idea about the FVII deficiency mutational profile in
our country.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/1288044089753085
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Factor VII deficiency is an inherited rare bleeding disorder,
which results from decreased or absence of coagulation
FVII. Factor VII deficiency is transmitted according the
autosomic way and affects 1/500000 population [1]. The
clinical features are heterogeneous, ranging from severe
life-threatening hemorrhages, such as cerebral, gastro-
intestinal, and joint hemorrhages, to miscellaneous minor
bleeding. The severity isn’t correlated with FVII activities
residual levels. FVII is a serine protease which accelerates
the prothrombin conversion. F7 gene which encodes co-
agulation molecule responsible for blood coagulation was
discovered in 1987. It is located on chromosome 13q34
and contained 9 exons. More than 200 mutations were* Correspondence: hejer.abdalah@gmail.com
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distribution, and reproduction in any mediumidentified in the entire F7 gene, especially punctual muta-
tions. The genotype-phenotype relationship in FVII defi-
ciency is variable [1,2]. The clinical phenotype in patients
is generally more severe in homozygous or compound-
heterozygous than heterozygous patients [2]. In Tunisia,
according to the World Federation of Hemophilia (WFH)
global survey 2009 [3], 15 patients with FVII deficiency
are reported. Twelve of them belong to our Hemophilia
Treatment Center of Aziza Othaman. The reported data
concerning FVII deficiency in Tunisia were interested in
the determination of some polymorphisms frequencies or
in the study of molecular defect only in Tunisian Jewish
patients [4-6]. The main objective of this study has been
to identify the molecular defects in the F7 gene of
Tunisian patients and explain the phenotype data of our
patients based on their genotypes. In our knowledge thisentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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patients with FVII deficiency.
Material and methods
Patients
The studied subjects belonging to Hemophilia Treatment
Center of Aziza Othmana, Tunis were recruited between
2010 and 2011. In order to identify the molecular defects
of F7 gene, we included 10 patients (women-6, men-4)
from 8 unrelated families with factor VII activities (FVII:
C) ranging from 2% to 40%. Their age ranges between 14
and 64 years old. The hemorrhagic symptoms are pre-
sented in Table 1.
Methods
DNA extraction and amplification
An informed consent was obtained from each patient
prior to blood collection. DNA was extracted from white
blood cells by standard phenol chloroform extraction
method [7]. PCR primers were used for amplification of
the whole coding regions, the exon-intron boundaries
and the 5’ flanking region containing the promoter of F7
gene [8]. PCR was carried out in a 25 ml reaction
volume in ABI thermal cycle (Perkin-Elmer Applied Bio-
systems, Foster City, CA, USA).
Sequencing
Amplified regions were sequenced using ABI Dye Ter-
minator Cycle Sequencing (Perkin-Elmer Applied Bio-
systems, Foster City, CA, USA) and analyzed using aTable 1 Phenotype and genotype data of Tunisian patients w
Family Patient Age Symptoms FVII: C Mutation L
1 1 1992 Epistaxis, gastrointestinal,
dental extraction
23% p.F328Y* E




3 3 1992 Asymptomatic ND p.R304Q E
4 4 1991 Hemarthroses,
gingival, menorrhagia
40% IVS1a + 5 G>A I























8 10 1963 Menorrhagia, epistaxis 5% ND
*Novel mutation.
Nucleotide numbers are based on the full sequence published by O’hara et al 1987
acids is based on Genebank file NM-000131. Methionine is numbered as −60.
Polymorphisms: M1: Arg at position 353, M2: Gln at position 353. P0: no insertion o
promoter. A1: nt C at position −122 in promoter, A2: nt T at position −122 in promo
ND: not determined.capillary sequencer Genetic Analyser ABI PRISM310
(Perkin-Elmer Applied Biosystems, Foster City, CA,
USA). Results were analyzed using BLAST program
(http://www.ncbi.nlm.nih.gov/blast) against the normal
F7 gene sequence and the mutations were compared




The symptoms observed in our patients are epistaxis,
menorrhagia, bruising and metrroragia. The unique
episode of hematoma was observed in one woman
after trauma. No patients had experienced intracra-
nial hemorrhage (Table 1). Only five patients are
treated with prothrombin complex concentrate
(PCC).
Molecular data
Ten fragments corresponding to putative promoter, cod-
ing regions and exon-intron boundaries of the F7 gene
were screened for mutation by PCR/sequencing method.
A list of potentially pathogenic mutations and poly-
morphisms of the F7 gene is shown in Table 1. The pos-
ition of mutations and polymorphisms are based on the
original F7 gene reported by O’Hara [9].
We identified 5 different mutations in 5 unrelated
patients. The mutations are composed of three missense
mutations and 2 splicing site mutations. Among them
one mutation is novel.ith FVII deficiency
ocation Domain Type Genotype Polymorphism
xon 8 Cataltytic Missense Heterozygous M1M1, P0/P0, A1/A1,H5
xon 8 Cataltytic Missense Heterozygous M1M2, P0/P10, A1/A2,H5
xon 8 Cataltytic Missense Homozygous M1M1, P0/P0, A1/A1,H5
ntron 1a Propeptide Splicing Heterozygous M1M1, P0/P0, A1/A1,H5




using the A of the ATG initiator methionine as +1. Numbering of the amino
f 10 bp at position-323 in promoter, P10: insertion of 10 bp at position-323 in
ter.
Elmahmoudi et al. Diagnostic Pathology 2012, 7:92 Page 3 of 5
http://www.diagnosticpathology.org/content/7/1/92Missense mutations (n = 3)
The 3 missense mutations were detected within the F7
gene (Figure 1) in exon 8; a novel heterozygous mutation
p.F328Y (TTC!TAC) in patient 1, a reported heterozy-
gous p.M298I (ATG!ATA) in patient 2 and a reported
homozygous G>A transition leading to p.R304Q substitu-
tion (CGG!CAG) in patient 3 (Table 1).Figure 1 Localization of identified mutations in 5 unrelated
Tunisian patients with FVII deficiency. The 3 punctual mutations
are localized in the catalytic region within exon 8. The 2 splice
mutations are localized in intron 1 and in the exon 2. Nucleotide
numbers are based on the full sequence published by O’hara et al
1987 using the A of the ATG initiator methionine as +1. Numbering
of the amino acids is based on Genebank file NM-000131.
Methionine is numbered as −60.Splicing site mutations (n = 2)
Sequencing of exon/intron regions using genomic
DNA revealed a heterozygous splicing donor site mu-
tation IVS1a + 5 G >A (patient 4) and one silent muta-
tion p.G-39G (GGC>GGT) occurring in the heterozygous
state (patient 5). Since the silent mutation is located in+ 2
within the exon 1b it is considered as a splice site mutation
(Table 1).
Polymorphisms (n = 5)
Relating to FVII deficiency, there are various single nu-
cleotide polymorphisms known in F7 gene, which can
lead to an amino acid exchange and have impact on the
FVII levels [10]. The investigation of all patients revealed
previously described polymorphisms in heterozygous
forms concerning 3 patients (patient 2, 5 and 10). The
p.R353Q (M1/M2) polymorphism was identified in
heterozygous state in patient 2. The 10 bp promoter
insertion of nucleotide −323 (P0/P10) and the poly-
morphic variation -122 T>C (A1/A2) in the promotor
region were found in heterozygous state in 2 patients
(patient 2 and 5). The repeat polymorphism of intron 7
was identified in one patient (Table 1).
Discussion
Some substitutions modified directly or indirectly, the
binding of factor VII to tissular factor. In our patients
we identified 3 missense mutations the novel p.F328Y
and the two reported p.R304Q and p.M298I. The novel
p.F328Y involves the substitution of a non polar amino
acid (F) by a neutral amino acid (Y) in the catalytic do-
main of the factor VII which may be affects its affinity in
binding to the tissular factor. Using PolyPhen, this sub-
stitution is predicted to be probably damaging with a
score of 1.000 (sensitivity: 0.00; specificity: 1.00). Others
studies demonstrate that the p.F328S mutation reduces
tissue factor binding, impairs activation by factor Xa and
abolishes the coagulant activities [11,12]. Since our novel
mutation p.F328Y occurs in the same position as the
reported mutation p.F328S, we hypothesis that the
p.F328Y may be plays the same role by the reduction of
tissue factor binding. The mutation p.F328S is reported
in homozygous state and in compound heterozygous
state and it is associated with severe phenotype [2]. In
our patient the novel mutation p.F328Y is identified in
heterozygous state which may be explain the moderate
phenotype.
The reported mutations p.M298I and p.R304Q
described in the literature, which occur also in the cata-
lytic domain disrupt interactions between factor VII and
tissular factor [13,14].
The p.M298I identified in heterozygous state in our
patient (patient 2) and also described with the same state
[15], is responsible for an inefficient activation of the
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patients when it is in the heterozygous state while in our
patient it is associated with epistaxis, dental extraction, gin-
gival and menorrhagia. This may be explained by the pres-
ence in heterozygous state of the 3 SNPs; M1M2, P0/P10
>and A1/A2 predicted to reduce the FVII activity [10].
The p.R304Q is reported in homozygous and heterozy-
gous state in many countries indicating that it is a fre-
quent and recurrent mutation [16,17]. In our patient
(patient 3) it is associated with homozygous state. Cor-
relation genotype/phenotype for this mutation is in ac-
cordance with reported data since this mutation is
associated with asymptomatic or paucisymptomatic
patients [18], which is the case for our patient who is
asymptomatic.
The 2 splicing mutations IVS1a + 5 G >A and the
p.G-39G identified in the heterozygous state respectively
in patients 4 and 5, are associated with hemarthrosis, gin-
gival, menorrhagia and epistaxis: clinical symptoms asso-
ciated with heterozygous mutations described above
[19,20]. For the patient 5 the presence of the SNPs A1/A2
known to decrease 25% of the FVII levels [21] may also
has an effect on the phenotype of our patient.
Among the 5 identified mutations, 3 are localized in the
exon 8 (catatytic region) which represent the hot spot re-
gion of F7 gene as reported in literature [10]. Only the p.
R304Q occurred within the CpG dinucleotides.
No mutations were found in 5 patients from 3 unre-
lated families with reduced FVII activities (2.5% to 5%)
and they share all the wild alleles in the homozygous
state concerning the M1, P0 and A1 SNPs. Only patient
number 10 represent 7 repetitions of polymorphism H
in exon 7 which may be responsible for the reduced
FVII activity. Others data reported also the absence of
molecular defect in some patients in their series [17].
The cause may be an intragenic rearrangement escaping
our procedure, so we investigate the use of other techni-
ques such as semi-quantitative multiplex PCR or MLPA.
A unique study described molecular pathology within
FVII deficiency in Tunisian patients concern Tunisian
Jewish [6]. In this study they identified the p.R304Q mu-
tation which is also present in one of our patients des-
pite their different origin, the p.R304Q is a recurrent
mutation known in different ethnics groups and popula-
tions. The others mutations described in this study are
different from our identified mutations which confirm
the Arabic origin of our patients.
A few Tunisian studies were interested in the distribu-
tion of some polymorphisms (M1/M2 and P0/P10) in
patients with FVII deficiency and healthy groups from
different Tunisian regions demonstrate that the most
frequent alleles are M1/M1 and P0/P0 in all the studied
groups and also in groups from the North of Tunisia
[4,5]. This distribution is confirmed in our patients whoare from the North and in whom we identified only one
allele M1/M2 in one patient/7 unrelated patients and we
found the allele P0/P10 only in 2 patients. All the others
patients are homozygous for the frequent alleles cited
above.
Conclusion
This represents the first comprehensive molecular series
of FVII deficiency affected patients in Tunisia. We iden-
tified 5 different mutations, one of them is novel. For 5
patients we didn’t identify any mutation with PCR/
Sequencing protocol used in this study that’s why we in-
vestigate other approaches to identify the molecular
defects in these patients. Since our patients are from the
North province of Tunisia, we will try in the future to
continue the molecular study for Tunisian patients from
Center and South provinces in order to have a complete
idea about the FVII deficiency mutational profile in our
country. This allows us to understand the genotype/
phenotype relations of this pathology since it has a
heterogeneous clinical manifestation.
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